NMT Medical
ORG
NMT Medical NMT
Although the maker of the implanted device that repairs a congenital heart defect can reduce the frequency and severity of migraine headaches, NMT Medical, called the preliminary findings promising, the results disappointed investors because NMT had been seeking a definitive finding that the device could stop the headaches. Shares of the company, which is based in Boston, plunged nearly 33 percent in heavy trading yesterday after the findings were announced, closing at $14.04. The clinical trial, which took place in Britain, used NMT Medical's StarFlex device to close a hole between the upper chambers of the heart that as many as 25 percent of adults have from birth. ANMT Medical, called the preliminary findings promising, but the results disappointed investors because NMT had assured that the device could stop the headaches. Shares of the company, plunged nearly 33 percent in heavy trading after the findings were announced, closing at $14.04. The clinical trial, which took place in Britain, used NMT Medical's StarFlex device to close a hole between the upper chambers of the heart that as many as 25 percent of adults have from birth.